TR199900951T2 - Gögüs kanserinin engellenmesi için yöntemler. - Google Patents

Gögüs kanserinin engellenmesi için yöntemler.

Info

Publication number
TR199900951T2
TR199900951T2 TR1999/00951T TR9900951T TR199900951T2 TR 199900951 T2 TR199900951 T2 TR 199900951T2 TR 1999/00951 T TR1999/00951 T TR 1999/00951T TR 9900951 T TR9900951 T TR 9900951T TR 199900951 T2 TR199900951 T2 TR 199900951T2
Authority
TR
Turkey
Prior art keywords
breast cancer
prevention
methods
solvates
person
Prior art date
Application number
TR1999/00951T
Other languages
English (en)
Inventor
J. Cohen Fredric
S. Eckert Robert
E. Glusman Joan
K. Knickerbocker Ronald
T. Nickelsen Nikolaus
J. Scott Teri
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27268608&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR199900951(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9624800.0A external-priority patent/GB9624800D0/en
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of TR199900951T2 publication Critical patent/TR199900951T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Gögüs kanserinin engellenmesi için bir yöntem olup, bu yöntem, ihtiyaç duyan bir insana, yeterli bir süre için, (I)formülüne sahip olan bir bilesigin ya da farmasötik açidan kabul edilebilir tuzlari ve solvatlarinin etkili bir miktarinin tatbik edilmesini içermektedir.
TR1999/00951T 1996-10-30 1997-10-29 Gögüs kanserinin engellenmesi için yöntemler. TR199900951T2 (tr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2985096P 1996-10-30 1996-10-30
GBGB9624800.0A GB9624800D0 (en) 1996-11-29 1996-11-29 Methods of preventing breast cancer
US4026097P 1997-03-10 1997-03-10

Publications (1)

Publication Number Publication Date
TR199900951T2 true TR199900951T2 (tr) 1999-07-21

Family

ID=27268608

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/00951T TR199900951T2 (tr) 1996-10-30 1997-10-29 Gögüs kanserinin engellenmesi için yöntemler.

Country Status (43)

Country Link
US (2) US6303634B1 (tr)
EP (3) EP0839532B1 (tr)
JP (2) JPH10147529A (tr)
CN (2) CN1182590A (tr)
AP (1) AP971A (tr)
AR (2) AR010538A1 (tr)
AT (2) ATE338551T1 (tr)
AU (3) AU5005697A (tr)
BE (2) BE1011382A5 (tr)
BG (1) BG63841B1 (tr)
BR (1) BR9712703A (tr)
CA (2) CA2219070C (tr)
CH (2) CH693820A5 (tr)
CZ (2) CZ300261B6 (tr)
DE (2) DE69721692T2 (tr)
DK (2) DK1369115T3 (tr)
EA (2) EA006083B1 (tr)
EE (1) EE03663B1 (tr)
ES (4) ES2135343A1 (tr)
FR (2) FR2755014B1 (tr)
GB (3) GB2318734B (tr)
GE (1) GEP20032910B (tr)
GR (2) GR1003189B (tr)
HU (2) HUP9701777A3 (tr)
IE (2) IE970772A1 (tr)
IL (2) IL122026A0 (tr)
IS (1) IS5035A (tr)
IT (2) ITMI972434A1 (tr)
LU (2) LU90157B1 (tr)
LV (1) LV12353B (tr)
MY (1) MY121623A (tr)
NL (2) NL1007386C2 (tr)
NO (2) NO322468B1 (tr)
NZ (1) NZ329042A (tr)
PT (2) PT1369115E (tr)
RO (1) RO120813B1 (tr)
SG (2) SG83672A1 (tr)
SI (3) SI1369115T1 (tr)
SK (1) SK287047B6 (tr)
TR (1) TR199900951T2 (tr)
UA (1) UA46762C2 (tr)
WO (2) WO1998018325A1 (tr)
YU (1) YU42397A (tr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458811B1 (en) * 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
GB9624800D0 (en) * 1996-11-29 1997-01-15 Lilly Co Eli Methods of preventing breast cancer
FI982733L (fi) * 1998-12-17 2000-06-18 Orion Yhtymae Oyj Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
FI109332B (fi) 1998-12-17 2002-07-15 Orion Yhtymae Oyj Toremifeenin liukoisia koostumuksia
EP1401446B1 (en) 2001-05-22 2005-02-09 Eli Lilly And Company Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen
EP1395563B1 (en) 2001-05-22 2006-03-29 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
US20040225200A1 (en) * 2003-05-09 2004-11-11 Edmundson Catherine M. System and method of analyzing the health of a population
GR1005694B (el) * 2005-06-08 2007-10-22 Αλεξης Μιχαηλ Ιστοειδικα αντιοιστρογονα ειδικα για τον αλφα υποδοχεα των οιστρογονων
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
WO2011099942A1 (en) 2010-02-09 2011-08-18 Silverstone Pharma New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy
CN102973573B (zh) * 2012-11-28 2015-04-08 玉林师范学院 一种人乳腺癌细胞抑制剂及制备方法
CN103830197A (zh) * 2014-03-14 2014-06-04 崔书豪 一种盐酸雷洛昔芬分散片及其制备方法
CN116650484A (zh) * 2023-05-11 2023-08-29 南通大学 一种乳腺癌相关蛋白的抑制剂及其应用
MX2023013107A (es) * 2023-11-06 2025-06-02 Centro De Investig Y De Estudios Avanzados Del I P N Composiciones sinergicas de loratadina-raloxifeno-sorafenib para el tratamiento de cancer hepatico.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
CZ253694A3 (en) * 1993-10-15 1995-05-17 Lilly Co Eli Pharmaceutical preparation for treating resistant neoplasms
US5478847A (en) * 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
IL112746A (en) * 1994-03-02 1999-12-31 Lilly Co Eli Orally administrable pharmaceutical formulation comprising raloxifene hydrochoride
US5604248A (en) * 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
US5521214A (en) * 1995-01-25 1996-05-28 Eli Lilly And Company Methods of inhibiting environmental estrogens
US5821254A (en) 1995-02-17 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer
JP2000507268A (ja) * 1996-03-26 2000-06-13 イーライ・リリー・アンド・カンパニー ベンゾチオフェン類、それを含む製剤、および方法

Also Published As

Publication number Publication date
CZ341297A3 (cs) 1998-05-13
LU90157B1 (fr) 1998-06-02
GEP20032910B (en) 2003-03-25
MX9708341A (es) 1998-08-30
AU4364897A (en) 1998-05-07
DK1369115T3 (da) 2007-01-02
AU5005197A (en) 1998-05-22
YU42397A (sh) 2000-10-30
EA002054B1 (ru) 2001-12-24
NO322468B1 (no) 2006-10-09
EP0839532A1 (en) 1998-05-06
EE9900162A (et) 1999-12-15
HUP9701777A2 (hu) 1999-06-28
DE69721692D1 (de) 2003-06-12
ES2271476T3 (es) 2007-04-16
SI20107A (sl) 2000-06-30
LV12353A (lv) 1999-10-20
AU5005697A (en) 1998-05-22
SG72765A1 (en) 2000-05-23
US6303634B1 (en) 2001-10-16
JPH10147529A (ja) 1998-06-02
CH691847A5 (fr) 2001-11-15
DK0839532T3 (da) 2003-08-25
PT1369115E (pt) 2006-12-29
ES2135342B1 (es) 2000-05-16
AU731388B2 (en) 2001-03-29
NO974972D0 (no) 1997-10-28
AR013864A1 (es) 2001-01-31
CA2219070C (en) 2007-12-18
JPH10147530A (ja) 1998-06-02
CZ300261B6 (cs) 2009-04-01
ES2197312T3 (es) 2004-01-01
IL122025A0 (en) 1998-03-10
ES2135343A1 (es) 1999-10-16
NO974972L (no) 1998-05-04
BR9712703A (pt) 1999-10-26
GB2318734B (en) 1999-12-01
WO1998018449A1 (en) 1998-05-07
IS5035A (is) 1999-04-27
FR2756490B1 (fr) 2003-06-20
NL1007387C2 (nl) 1998-05-14
EP1369115B1 (en) 2006-09-06
GR970100408A (el) 1998-06-30
FR2756490A1 (fr) 1998-06-05
BE1011381A5 (fr) 1999-08-03
ATE338551T1 (de) 2006-09-15
UA46762C2 (uk) 2002-06-17
ATE239475T1 (de) 2003-05-15
BE1011382A5 (fr) 1999-08-03
EA199900431A1 (ru) 1999-10-28
NZ329042A (en) 1999-08-30
CN1182590A (zh) 1998-05-27
GB2318733A (en) 1998-05-06
HUP9701778A2 (hu) 1999-01-28
AU4364797A (en) 1998-05-07
EA200100716A1 (ru) 2002-06-27
PT839532E (pt) 2003-09-30
DE69736644D1 (de) 2006-10-19
HU9701777D0 (en) 1997-12-29
HU9701778D0 (en) 1997-12-29
NO974973D0 (no) 1997-10-28
AP9901494A0 (en) 1999-03-31
EP1369115A1 (en) 2003-12-10
CH693820A5 (fr) 2004-02-27
IL122026A0 (en) 1998-03-10
ES2135342A1 (es) 1999-10-16
GR1003189B (el) 1999-09-01
GB9722801D0 (en) 1997-12-24
IE970773A1 (en) 2000-02-09
EE03663B1 (et) 2002-04-15
EP0839533A1 (en) 1998-05-06
DE69721692T2 (de) 2004-03-25
HUP9701777A3 (en) 1999-07-28
SK55999A3 (en) 2000-06-12
LV12353B (en) 2000-02-20
IE970772A1 (en) 2000-02-09
DE69736644T2 (de) 2007-10-25
NL1007386C2 (nl) 1998-05-14
AP971A (en) 2001-05-30
WO1998018325A1 (en) 1998-05-07
SI1369115T1 (sl) 2006-12-31
GB2318734A (en) 1998-05-06
SK287047B6 (sk) 2009-10-07
BG103369A (en) 2000-05-31
HK1010495A1 (en) 1999-06-25
FR2755014A1 (fr) 1998-04-30
US20020019418A1 (en) 2002-02-14
EA006083B1 (ru) 2005-08-25
IL122025A (en) 2003-01-12
EP0839532B1 (en) 2003-05-07
MY121623A (en) 2006-02-28
CZ341197A3 (cs) 1998-05-13
GR970100409A (el) 1998-06-30
FR2755014B1 (fr) 1999-02-05
CA2219070A1 (en) 1998-04-30
LU90158B1 (fr) 1998-06-02
MX9708340A (es) 1998-08-30
ITMI972433A1 (it) 1999-04-29
GB9911557D0 (en) 1999-07-21
AR010538A1 (es) 2000-06-28
HUP9701778A3 (en) 1999-06-28
SG83672A1 (en) 2001-10-16
BG63841B1 (bg) 2003-03-31
GB9722796D0 (en) 1997-12-24
SI0839532T1 (en) 2003-10-31
ITMI972434A1 (it) 1999-04-29
IT1298470B1 (it) 2000-01-10
CN1182591A (zh) 1998-05-27
RO120813B1 (ro) 2006-08-30
CA2219377A1 (en) 1998-04-30

Similar Documents

Publication Publication Date Title
TR199801315T2 (tr) X sendromunun tedavisi için bir ppar-alpha ve ppar-gamma antagonistinin kullanilmasi.
DK0768885T3 (da) Fremgangsmåde til inhibering af cancermetastase ved oral administration af oplöselig modificeret citruspectin
DE69129861D1 (de) Topische mittel zur transdermalen verabreichung von prodrugderivaten des morphins
NO931635D0 (no) Fremgangsmaate for fremstilling av kinazolin-derivater
TR200002855T2 (tr) Raloksifenin solunum yolu ile veya burundan uygulanması.
SI0889886T1 (en) Novel phenanthridines substituted in the 6 position
DE69738667D1 (de) Vorbeugung und behandlung von kolonadenom oder kolonmikroadenom mit 6-fluorursodeoxycholsäure
TR199800077T1 (tr) Kontrollü çözülen paroksetin terkipleri.
PL323490A1 (en) Tetralinic compounds exibiting acitity against multgiple-drug refractoriness
DE69637050D1 (de) Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer
EA200100716A1 (ru) Способ профилактики рака молочной железы
EE9800435A (et) H+, K+-ATPaasi inhibiitorite manustamise reziim
DE69030649D1 (de) Polysaccharide derivate sowie trennmittel
IL141686A0 (en) Methods of treating hypertension and compositions for use therein
SI0934065T1 (sl) Novi kriptoficinski derivati kot anti-neoplasticna sredstva
BG101875A (en) New cryptoficins and method for their preparation
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
DK0986393T3 (da) Anvendelse af et nitroxid eller et prodrug heraf ved profylaktisk og terapeutisk behandling af cancer
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
IL131478A0 (en) Methods for treatment of scar tissue
TR199802496T2 (tr) Konjestif kalp yetmezligini tedavi için formülasyon.
ATE397615T1 (de) 6-o-alkyl-2-nor-2-substituierte ketolidderivate
ATE221542T1 (de) Wasserlösliche glykolisierte derivate von 1,2- dithiinverbindungen
MX9804068A (es) Nuevos derivados de quinoxalindiona, su preparacion y empleo en medicamentos.